-$0.04 Earnings Per Share Expected for Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM) This Quarter

Wall Street brokerages expect Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM) to post ($0.04) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Actinium Pharmaceuticals’ earnings. Actinium Pharmaceuticals reported earnings per share of ($0.06) in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The company is expected to announce its next earnings report on Tuesday, March 17th.

On average, analysts expect that Actinium Pharmaceuticals will report full year earnings of ($0.16) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($0.17) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Actinium Pharmaceuticals.

Actinium Pharmaceuticals (NASDAQ:ATNM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04).

Shares of ATNM traded down $0.01 during trading hours on Friday, hitting $0.27. The company had a trading volume of 3,216,090 shares, compared to its average volume of 4,809,892. The stock has a fifty day moving average price of $0.24. Actinium Pharmaceuticals has a 12 month low of $0.19 and a 12 month high of $0.71.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Featured Story: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.